Akumin — Q3 2021 Earnings Presentation
31 slides from Akumin's earnings presentation, December 2021
Slide 1: Corporate Presentation
Akumin Inc. Corporate Presentation December 2021 Riadh Zine, Chairman & Co-CEO Rhonda Longmore-Grund, President & Co-CEO Bill Larkin, Chief Financial Officer
Slide 2: Disclaimer and Disclosure
Disclaimer and Disclosure Forw ard-Looking Statements This presentation may contain forward-looking information or forward-looking statements w ithin the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities legislation (collectively, “forward-loo
Slide 3: Today's Presenters
Today’s Presenters Riadh Zine Rhonda Longmore-Grund Bill Larkin Chairman of the Board and Co-CEO President and Co-CEO Chief Financial Officer • Akumin’s CEO since it started in 2014, now • Previously President and Chief Executive • Previously Executive Vice President & Chief serves as Chairman and C
Slide 4: Akumin At a Glance
Akumin At a Glance • #2 overall radiology services provider: ~2 million procedures/year in 46 states • #1 provider of PET/CT services • #2 provider of MRI services • #2 fixed site clinic locations • #1 mobile radiology provider • #2 provider of radiation therapy services to U.S. hospitals treating m
Slide 5: Long-Standing Health System Relationships
Long-Standing Health System Relationships The Nation’'s Largest and Leading Health Systems Radiology & Oncology • 30+ year history of successful hospital partnerships • ~1,000 hospital relationships within Radiology and Oncology networks • Serving 25 of the top 30 hospitals in the nation • Deep part
Slide 6: Flexible Approach Focused on Fixed Site Development & Growth
Flexible Approach Focused on Fixed Site Development & Growth • Comprehensive solutions Mobile On-Campus Outpatient Outpatient Fixed Sites Fixed Sites Networks delivered through a flexible • Market or regional approach to partnership • Shared platform, part- • Within or adjacent to • Convenient locat
Slide 7: Outpatient-Focused Platform
Outpatient-Focused Platform ~95% of the company’s overall revenue is derived from outpatient procedures Overall Payor Mix Hospital Mix of Outpatient (% of Revenue) (% of Revenue) • 50% of revenue is received Inpatient via third party and Revenue 3% government payers, for which we bill outpatient Med
Slide 8: Diverse Service Lines and Modalities
Diverse Service Lines and Modalities • Continued diversification of Service Lines revenue between Radiology (% of Revenue) and Oncology divisions Radiology Procedure Mix (% of Revenue) • Akumin provides a full suite of radiology and oncology 20% 20% services with a focus on high- growth and high-val
Slide 9: A Powerhouse in Radiology
A Powerhouse in Radiology Total Radiology Volume/Year Akumin is the nation’s #2 overall radiology company, (Pro Forma) 2,134,415 with more than 2 million patient visits per year 2,006,759 Akumin is the nation’s #2 MRI provider 1,916,412 • A critical diagnostic tool for complex health conditions and
Slide 10: The Nation's #2 Partner in Radiation Therapy Services with Hospitals
The Nation’s #2 Partner in Radiation Therapy Services with Hospitals • ~2/3 of cancer patients receive radiation • Akumin excels in Joint Venture partnerships therapy as part of their cancer treatment with hospitals and physicians and in delivering this complex clinical service line • Akumin special
Slide 11: Uniquely Positioned as a Hospital Partner of Choice
Uniquely Positioned as a Hospital Partner of Choice Patient Care Continues to Coalesce As Hospitals Shift to Outpatient Services, Around the Hospital Network Akumin is Their Most Experienced 91% of final-year medical residents report that Partner they prefer to be an employee of a hospital Hospital
Slide 12: Expert Solutions Provider As Radiology Outpatient Migration Accelerates
Expert Solutions Provider As Radiology Outpatient Migration Accelerates Positive forces on radiology volume growth • Population change, consumerism, disease prevalence, technology; dampened by continued payer actions Hospital Imperative Deploy a full suite of services to Outpatient migration continu
Slide 13: Strategic Partner in a Cancer Care Market Demanding Efficiency and Collaboration
Strategic Partner in a Cancer Care Market Demanding Efficiency and Collaboration COVID-19 impacts are ongoing and evolving Cancer incidence, overall, continues to grow • Many cancer screening monthly volumes have • Number of newly diagnosed cancers per year is projected returned to pre-pandemic leve
Slide 14: Significant Market Opportunity With Favorable Industry Trends
Significant Market Opportunity With Favorable Industry Trends Radiology Oncology ~$16-17 billion ~$3 billion Estimated Market Size Estimated Radiation Therapy Market Size Radiology is essential to healthcare delivery and utilized in Radiation therapy is essential to virtually all clinical specialtie
Slide 15: Growth Strategy: Driving Shareholder Value
Growth Strategy: Driving Shareholder Value Deliver Enterprise Drive New Growth in Drive New Growth in Enterprise Organic Growth Radiology Oncology Transformation Market, Partner Market Leadership & Deepen Cancer Care Strategic Shift & Market & Company Health Performance Value Proposition Differentia
Slide 16: Enabling Value Creation Via Operational Platform Transformation
Enabling Value Creation Via Operational Platform Transformation We are building innovative standardization in • Patient journey • Clinical workflow • Data Focused on creating a scalable service Patient delivery platform Experience Because delivering exceptional patient engagement and experiences is
Slide 17: Integration Cost Synergy Potential
Integration Cost Synergy Potential Integration Cost Synergy Potential The $23 million in estimated cost synergies are related to phase 1 and equipment maintenance overhaul in phase 2. More upside in cost savings expected to arise from a number of initiatives as outlined in both phase 2 and phase 3.
Slide 18: Financial Performance
Financial Performance
Slide 19: Radiology Volume Trends – Pro Forma
Radiology Volume Trends – Pro Forma • Same Store MRI Volume Growth: +8.5% in Q3 2021 • Same Store PET/CT Volume Growth: +2.2% in Q3 2021 • Same Store Total Procedures Volume Growth: +8.9% in Q3 2021 Same Store Volume Growth Total Volumes MRI PET/CT Total Procedures 19
Slide 20: Oncology Volume Trends – Pro Forma
Oncology Volume Trends – Pro Forma • Same Store Patient Start Volume Growth: 10.1% in Q3 2021 • Patient Start Volume has returned to pre-Covid (2019) levels • Revenue/Patient Start is higher than pre-Covid (2019) levels Same Store Patient Start Volume Growth Total - Patient Starts Volume1 Total - Re
Slide 21: Financial Performance Trend Statutory (As Reported) and Pro Forma
Financial Performance Trend Statutory (As Reported) and Pro Forma Revenue1 Adjusted EBITDA2 ($M) ($M) Maintenance CAPEX3 Growth CAPEX3 ($M) ($M) 1 P ro forma includes A lliance O ncology of A rizona (div ested Q 4 2021) w hich contributed $ 13.2M of Rev enue TTM and Interv entional Div ision (div es
Slide 22: Segment Financial Performance Statutory & Pro Forma
Segment Financial Performance Statutory & Pro Forma Q3 2021 Q3 2021 YTD ($ in M) RAD ONC Corp Total ($ in M) RAD ONC Corp Total Revenue $ 95.0 $13.2 $ - $ 108.2 Revenue $228.5 $ 13.2 $ - $ 241.6 % vs prior year 50.3% n/m 71.1% % vs prior year 27.8% n/m 35.2% Adjusted EBITDA $ 16.6 $ 4.9 $ (3.5) $ 18
Slide 23: Guidance & Valuation
Guidance & Valuation ©)akumin:
Slide 24: 2022 Guidance
2022 Guidance • Full year of combined enterprise • Positive same store volume across the platform • Strong new customer acquisition as well as retention • Revenue range $760M-$780M • Sept 2021 TTM Revenue of $309M. Includes one month of Alliance acquisition vs twelve months in 2022 guidance. • Adjus
Slide 25: Free Cash Flow Generation
Free Cash Flow Generation The company expects to generate free cash flows of ~$55mm as per the following assumptions: LTM 2022 2022 • Mid range of the 2022 Sep 30 2021 Midpoint Runrate guidance Adjusted EBITDA(1) $ 42.1 $ 160.6 $ 186.8 (2) • Full deployment of 2022 Less: Growth CAPEX of $59M and Mai
Slide 26: Capital Structure – A Solid Foundation for Growth
Capital Structure – A Solid Foundation for Growth (US$ millions, unless noted) Strong Alignment Share Price ($) $ 1.70 of Interests Total Shares Outstanding (mm) 89.0 Management and insiders, Equity Value $ 151.3 including Stonepeak, own approximately 40% resulting in Total Secured Debt $ 903.2 stro
Slide 27: Strong Partners Well-Aligned With Shareholders
Strong Partners Well-Aligned With Shareholders • The support of Stonepeak was integral to the successful completion of the Alliance acquisition and, through its subordinated notes, equity position and warrant holdings, is well-aligned with shareholders as key beneficiaries of Akumin’s future growth.
Slide 28: Thank you!
Thank you! Riadh Zine, Chairman & Co-CEO Rhonda Longmore-Grund, President & Co-CEO Bill Larkin, Chief Financial Officer
Slide 29: Net Income to Adjusted EBITDA Reconciliation
Appendix 1: Net Income to Adjusted EBITDA Reconciliation ~AKUMIN" (Restated- (Restated- Note 4) Note 4) Three months Three months Nine months Nine months ended ended ended ended September 30, September 30, September 30, September 30, 2021 2020 2021 2020 Net income (I oss) $ 1, 180 $ (6,376) $ (8, 18
Slide 30: Income Statement
Appendix 2 Income Statement Three months ended September 30, (Restated-Note 4) Three months ended September 30, Nine months ended September 30, (Restated-Note 4) Nine months ended September 30, ~AKUMIN" 2021 2020 2021 2020 Revenues $ 108, 177 $ 63,213 $ 241,636 $ 178,747 Operating expenses: Cost cl
Slide 31: Balance Sheet
Appendix Appendix 3: 3: (Restated-Note 4) Balance Balance Sheet ASSETS Sheet September 30, 2021 December 31, 2020 ~AKUMIN" Current assets: Cash $ 55,876 $ 44,396 Acc ounts receilable 135,208 62,259 Prepaid expenses 1 1,815 2,996 Other current assets 3,232 1,435 Total current asset s 206, 131 111 ,08